TENAYA THERAPEUTICS INC
TNYANASDAQTrading Snapshot
- Day Range
- $0.59 – $0.60
- 52-Week Range
- $0.53 – $2.35
- Volume
- $3.73B
- Avg Volume
- $2.88B
- Shares Outstanding
- 217.0M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $1M
- Last Q Revenue
- $1M
- P/E Ratio
- -1.1
- P/S Ratio
- 95.9x
- EPS (TTM)
- $-0.47
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +77.0%
Why Investors Own TNYA
- ✓High-growth profile — revenue up +10.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 24% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
TENAYA THERAPEUTICS INC
TNYA
StockOtter · stockotter.spaceAbout TENAYA THERAPEUTICS INC
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therap
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics Additional Data Releases Plus Updates on Regulatory Discuss